Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Arnika Forte is a specialized combination product developed by DermAvance, designed to accelerate the healing of bruising and swelling following surgical procedures, cosmetic injectables, or physical trauma. The formulation synergistically combines *Arnica montana*, a botanical extract, and bromelain, a proteolytic enzyme derived from pineapple. *Arnica montana* contains sesquiterpene lactones, such as helenalin, which exert anti-inflammatory effects by inhibiting the transcription factor NF-kappaB. Bromelain acts as a proteolytic agent that breaks down fibrin and reduces plasma kinins, thereby decreasing vascular permeability and edema. The product is available in both oral capsule and topical roll-on formats, often used by dermatologists and plastic surgeons to improve patient recovery times and aesthetic outcomes post-procedure.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Arnika Forte.